This is all your personal interpretation. Covid is far from over. With thousands dying each day, the need is over? I don’t think so. Not to mention when the mild/moderate trial completes. When good results result in an EUA it will change the dynamics of treating Covid.
Presently there are infusion centers where patients must come in and sit for at least and hour to get other MAB’s. Leronlimab will change treatment options condsiderably. People will be able to just pull up in their car get a quick subcutaneous injection and be on their way. This will be a massive change for healthcare systems around the world.
The science keeps getting better and more data keeps coming forward for CCR5. The company will continue to move forward.
Some will continue to play the DOJ/SEC card but they are investigating short sellers not CYDY. However some will continue to use this thesis to cast doubt and try to discourage new investors.
My question is this: if the drug is truly a failure why are there so many casting doubt with relentless attacks? The trials should speak for themselves.
This is not the case and anyone that has done their due diligence knows this to be true.
The management team continues to improve man’s the right players are now onboard to bring Leronlimab across the finish line. 2022 will be the year for Cytodyn.
Longs know what they own and will be greatly rewarded. Especially since shorts and MM have driven the PPS so low. With prices this low even if the company was bought out at a low price it would definitely be higher than $5-$10 which would mean a decent profit for those buying now.
But go ahead and paint paint the doom and gloom thesis. We shall see who will have the last laugh. Let’s revisit this at the end of the year and see who was correct.
Market Data 
Markets 
AI
